93489-13-5

Basic information

• Product Name: 2 4-DIMETHOXYBENZYL ISOCYANATE 97
• Synonyms: 2 4-DIMETHOXYBENZYL ISOCYANATE 97;2,4-DIMETHOXYBENZYL ISOCYANATE, 97%;1-(isocyanatomethyl)-2,4-dimethoxybenzene
• CAS NO: 93489-13-5
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.19924
• Product Categories: Isocyanates;Nitrogen Compounds;Organic Building Blocks
• Mol File: 93489-13-5.mol
• Article Data: 5

Chemical Properties

• Flash Point: 110 °C
• Appearance: /
• Density: 1.159 g/mL at 25 °C(lit.)
• Refractive Index: n20/D 1.5330(lit.)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2 4-DIMETHOXYBENZYL ISOCYANATE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 2 4-DIMETHOXYBENZYL ISOCYANATE 97(93489-13-5)
• EPA Substance Registry System: 2 4-DIMETHOXYBENZYL ISOCYANATE 97(93489-13-5)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-42
• Safety Statements: 23-26-36
• WGK Germany: 3
• Hazardous Substances Data: 93489-13-5(Hazardous Substances Data)

Usage

Molecular weight

211.22 g/mol

Physical state

Liquid

Appearance

Colorless to pale yellow liquid

Odor

Sharp, pungent

Reactivity

Highly reactive

Uses

Building block in the synthesis of various polymers and resins, utilized in the production of adhesives, coatings, and sealants

Functionality

Isocyanate functionality allows for the formation of strong and durable bonds, essential component in the manufacture of high-performance materials

Safety precautions

Can cause skin and respiratory irritation, proper safety precautions should be taken when working with it.

Upstream product

• 6496-89-5 2,4-dimethoxyphenylacetic acid 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 20781-20-8 2,4-Dimethoxybenzylamine 
• 75-44-5 phosgene 
• 20781-21-9 2,4-dimethoxybenzylamine hydrochloride 

Downstream Products

• 1161825-83-7 3-(2,4-dimethoxybenzyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 
• 848645-70-5 (R)-(-)-1,3-bis(2,4-dimethoxybenzyl)-4-vinylimidazolidine 
• 848645-71-6 (R)-(-)-N',N''-bis(2,4-dimethoxybenzyl)but-3-ene-1,2-diamine 
• 848645-60-3 (R)-(+)-1,3-bis(2,4-dimethoxybenzyl)-4-vinylimidazolidin-2-one 
• 425672-69-1 2-(4-{4-[N'-(2,4-dimethoxybenzylaminocarbonyl)hydrazino]-4-oxo-butyl}phenoxy)-2-methylpropionic acid tert-butyl ester 
• 1127892-22-1 C₄₁H₄₆N₂O₈S 
• 1010071-96-1 C₄₀H₅₆N₂O₇Si 
• 1010071-97-2 C₃₄H₄₂N₂O₇ 
• 1010071-98-3 C₃₄H₄₀N₂O₇ 
• 1010071-95-0 C₂₀H₃₂N₂O₅Si 
• 960540-86-7 ethyl 6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate 

Relevant articles and documents

Synthesis and growth-inhibitory activities of imidazo?5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position

A series of 3-(benzyl-substituted)-imidazo?5,1-d]-1,2,3,5-tetrazines (13) and related derivatives with 3-heteromethyl groups has been synthesised and screened for growth-inhibitory activity in vitro against two pairs of glioma cell lines with temozolomide-sensitive and -resistant phenotypes dependent on the absence/presence of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). In general the compounds had low inhibitory activity with GI50 values >50 μM against both sets of cell lines. Two silicon-containing derivatives, the TMS-methylimidazotetrazine (9) and the SEM-analogue (10), showed interesting differences: compound (9) had a profile very similar to that of temozolomide with the MGMT+ cell lines being 5 to 10-fold more resistant than MGMT- isogenic partners; the SEM-substituted compound (10) showed potency across all cell lines irrespective of their MGMT status.

3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

(-)-(3aS)-Eseroline carbamate (II), a potent cholinesterase inhibitor and close analogue of physostigmine: Reanalysis

(-)-Eseroline 8 on reaction with trimethylsilyl isocyanate in refluxing toluene directly gave the crystalline tricyclic urea 2. Carbamate 1 was made by debenzylation of 2′,4′-dimethoxybenzylcarbamate 17. The structures of carbamate 1 and tricyclic urea 2 were confirmed by X-ray crystallography. Carbamate 1, like physostigmine, was found to possess high inhibitory activity against human acetyl- (AChE) and butyrylcholinesterase (BChE) in vitro and potent action when administered to rats in in vivo studies.